Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis

Jennifer A. Kanakry, Yvette L. Kasamon, F Javier Bolanos Meade, Ivan M Borrello, Robert A Brodsky, Ephraim J Fuchs, Nilanjan Ghosh, Douglas Gladstone, Christopher Gocke, Carol Ann Huff, Christopher G. Kanakry, Leo Luznik, William Matsui, Huzefa J. Mogri, Lode Swinnen, Heather Symons, Richard J Jones, Richard F Ambinder

Research output: Contribution to journalArticle

Abstract

Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.

Original languageEnglish (US)
Pages (from-to)1514-1517
Number of pages4
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume19
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Lymphoproliferative Disorders
Graft vs Host Disease
Cyclophosphamide
Transplantation
Bone Marrow
Unrelated Donors
Incidence
Immunosuppressive Agents

Keywords

  • Allogeneic blood or marrow transplantation
  • Graft-versus-host disease prophylaxis
  • Post-transplantation cyclophosphamide
  • Post-transplantation lymphoproliferative disorder

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

@article{d4af104f7b404541aaf4ebb818131b76,
title = "Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis",
abstract = "Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67{\%}). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.",
keywords = "Allogeneic blood or marrow transplantation, Graft-versus-host disease prophylaxis, Post-transplantation cyclophosphamide, Post-transplantation lymphoproliferative disorder",
author = "Kanakry, {Jennifer A.} and Kasamon, {Yvette L.} and {Bolanos Meade}, {F Javier} and Borrello, {Ivan M} and Brodsky, {Robert A} and Fuchs, {Ephraim J} and Nilanjan Ghosh and Douglas Gladstone and Christopher Gocke and Huff, {Carol Ann} and Kanakry, {Christopher G.} and Leo Luznik and William Matsui and Mogri, {Huzefa J.} and Lode Swinnen and Heather Symons and Jones, {Richard J} and Ambinder, {Richard F}",
year = "2013",
month = "10",
doi = "10.1016/j.bbmt.2013.07.013",
language = "English (US)",
volume = "19",
pages = "1514--1517",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis

AU - Kanakry, Jennifer A.

AU - Kasamon, Yvette L.

AU - Bolanos Meade, F Javier

AU - Borrello, Ivan M

AU - Brodsky, Robert A

AU - Fuchs, Ephraim J

AU - Ghosh, Nilanjan

AU - Gladstone, Douglas

AU - Gocke, Christopher

AU - Huff, Carol Ann

AU - Kanakry, Christopher G.

AU - Luznik, Leo

AU - Matsui, William

AU - Mogri, Huzefa J.

AU - Swinnen, Lode

AU - Symons, Heather

AU - Jones, Richard J

AU - Ambinder, Richard F

PY - 2013/10

Y1 - 2013/10

N2 - Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.

AB - Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an increased incidence of post-transplantation lymphoproliferative disorder (PTLD) in the first year after transplantation. We evaluated the incidence of PTLD associated with the use of high-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Between 2000 and 2011, a total of 785 adult allo-BMT recipients were given PTCy as GVHD prophylaxis at the Johns Hopkins Hospital, including 313 patients who received PTCy as sole GVHD prophylaxis. HLA-haploidentical or unrelated donor graft transplantation was performed in 526 patients (67%). No cases of PTLD occurred during the first year after allo-BMT in this series. PTLD is a rare occurrence after allo-BMT using PTCy, even in high-risk alternative donor transplantations.

KW - Allogeneic blood or marrow transplantation

KW - Graft-versus-host disease prophylaxis

KW - Post-transplantation cyclophosphamide

KW - Post-transplantation lymphoproliferative disorder

UR - http://www.scopus.com/inward/record.url?scp=84884180614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884180614&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.07.013

DO - 10.1016/j.bbmt.2013.07.013

M3 - Article

C2 - 23871780

AN - SCOPUS:84884180614

VL - 19

SP - 1514

EP - 1517

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -